ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower from about $117.29 to $116.54, reflecting a series of reduced Street price targets that cite utilization and inflation headwinds, while still applying a modestly lower discount rate and a slightly softer future P/E assumption.

Analyst Commentary

Recent Street research on Abbott Laboratories points to a more cautious tone, with many price targets cut and utilization and inflation flagged as key issues. Even so, there are still some constructive angles that matter if you are weighing Abbott against other large medtech stocks.

Bullish Takeaways

Bullish analysts still see Abbott as part of a broader medtech group where long term demand for procedures and devices can support earnings, even if near term utilization is softer than hoped.
Some research commentary acknowledges that valuations across large cap medtech already reflect a fair amount of utilization risk, which can limit further downside if execution remains steady.
Policy developments around structural heart procedures, such as expanded coverage for transcatheter aortic valve replacement, keep Abbott in a market where overall procedure volumes could benefit the category, even if peers are seen as better positioned.
Incremental moves like a modest price target increase earlier in the period show that not all research is one way, and there is still interest in Abbott’s longer term growth drivers once near term headwinds are better understood.

Bearish Takeaways

Multiple bearish analysts have cut Abbott price targets, including several double digit reductions, which collectively pulls Street valuation expectations lower and aligns with the trimmed fair value estimate.
Concerns around a lower utilization environment weigh on 2027 medtech estimates, with Abbott grouped among companies where procedure volumes and service demand may not fully offset inflation and cost pressures.
Inflation is being treated as a more persistent headwind, with less assumed margin expansion for Abbott and peers, which directly affects modeled earnings power and justifies more conservative P/E assumptions.
Goldman Sachs removing Abbott from its U.S. Conviction List underscores a shift in conviction on execution and risk reward, even if the firm still covers the stock, and this influences how some investors frame upside versus downside.

What’s in the News for Abbott Laboratories

Abbott secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, described as the first dual glucose ketone sensors for people with diabetes. The company plans to launch these products in select European countries later this year and has expanded its partnership with MiniMed to integrate these sensors with MiniMed smart dosing systems. Source: company announcements and recent news reports, May 2026.
New Abbott data presented at the American Diabetes Association’s June 2026 Scientific Sessions highlight sharp increases in diabetic ketoacidosis hospitalizations across age groups and underline the potential role of dual glucose ketone monitoring in earlier risk detection. Libre Duo and Libre Duo 10 Day have also been submitted to the U.S. Food & Drug Administration. Source: company product related announcement, June 2026.
Abbott completed a US$23b acquisition of Exact Sciences, expanding its cancer diagnostics portfolio around Cologuard and newer liver and esophageal tests. Recent commentary notes Q1 2026 revenue growth of 7.8% alongside lower operating income and earnings per share and a larger debt load, which some analysts describe as supporting a cautious Hold stance. Source: recent news reports, June 2026.
The American Cancer Society reaffirmed Abbott’s Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options for average risk adults 45 and older. Both tests are used every three years and are supported by Abbott’s commercial infrastructure and patient navigation programs. Source: company product related announcement, May 2026.
In cardiovascular care, Abbott received U.S. FDA clearance for its Ultreon 3.0 OCT software platform and released late breaking trial data across pulsed field ablation and conduction system pacing technologies. The company cited high safety profiles and procedure guidance aimed at supporting more precise treatment of complex coronary disease and heart rhythm disorders. Source: company product related announcements, April 2026.

Valuation Changes for Abbott Laboratories

Fair Value: Trimmed slightly from $117.29 to $116.54 per share, reflecting modestly lower Street assumptions and updated modeling inputs.
Discount Rate: Reduced slightly from 8.00% to 7.87%, signaling a small adjustment to the required return used in valuing Abbott Laboratories stock.
Revenue Growth: Held essentially unchanged at about 9.74% in the long run model, indicating no material shift in the topline growth assumption.
Net Profit Margin: Kept broadly stable at roughly 15.94%, with no meaningful change to Abbott’s modeled long term profitability in the current update.
Future P/E: Eased slightly from 27.12x to 26.85x, indicating a modestly lower valuation multiple applied to Abbott Laboratories’ future earnings.

25 views

Key Takeaways

Strong demand from emerging markets and aging populations, along with new product launches, is expected to fuel sustained growth and diversify revenue streams.
Innovation in high-margin medical technologies and a diversified business mix will drive market share gains and support stable, long-term earnings.
Margin and revenue growth are threatened by pricing pressures, regulatory risks, intensifying competition, global volatility, and increased investment requirements across Abbott's core business segments.

Catalysts

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.What are the underlying business or industry changes driving this perspective?

The expansion of healthcare access and rising middle class in key emerging markets (such as India, China, Latin America, and the Middle East) is fueling robust growth in branded generics and biosimilars, highlighted by Abbott's record sales in these regions and imminent biosimilar launches; this trend is poised to drive sustained double-digit top-line growth and greater geographic revenue diversification.
The global demographic shift toward an aging population and increasing prevalence of chronic and lifestyle-related diseases (e.g., diabetes, cardiovascular disease) is underpinning strong, recurring demand for Abbott's diagnostics, nutrition (e.g., Ensure, Glucerna), and high-growth medical device franchises-supporting revenue acceleration and enhanced operating leverage.
Abbott's ongoing innovation in high-margin segments, most notably through the FreeStyle Libre franchise (with next-gen, dual-analyte sensors and new software integrations) and pipeline launches in structural heart and rhythm management devices, positions the company to capture incremental market share and drive net margin expansion.
Recent headwinds (COVID testing declines, China diagnostics procurement, and HIV funding) are transient and expected to lapse by 2026, while new product launches (biosimilars, next-gen devices, systems integration) and regulatory expansions are set to accelerate revenue growth and improve earnings visibility.
Abbott's ability to leverage existing infrastructure and cross-segment synergies in emerging markets, coupled with a diversified business mix across nutrition, diagnostics, devices, and established pharmaceuticals, reduces earnings volatility and should support stable long-term earnings and margin improvement.

Abbott Laboratories Earnings and Revenue Growth

Abbott Laboratories Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Abbott Laboratories's revenue will grow by 9.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.9% today to 15.9% in 3 years time.
Analysts expect earnings to reach $9.5 billion (and earnings per share of $5.45) by about June 2029, up from $6.3 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $11.3 billion in earnings, and the most bearish expecting $7.2 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.9x on those 2029 earnings, up from 25.2x today. This future PE is greater than the current PE for the GB Medical Equipment industry at 24.6x.
Analysts expect the number of shares outstanding to grow by 0.08% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.87%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Diagnostic sales are experiencing significant headwinds due to declining COVID testing demand, ongoing effects from volume-based procurement (VBP) in China, and reduced US foreign aid funding for HIV testing; if VBP-related price erosion or Chinese market volatility persists or worsens, it could create persistent downward pressure on Diagnostic division revenues and overall company top-line growth.
The company faces exposure to tariffs (expected ~$200 million impact) and adverse foreign exchange movements (ongoing EPS headwind of up to 4%), both of which could compress operating margins and earnings, particularly if trade tensions or global currency volatility intensifies.
Competitive bidding initiatives for continuous glucose monitors (CGM) in the US, coupled with rising competition from other CGM providers and potential commoditization of diagnostic and device platforms, threaten Abbott's pricing power and could erode net margins and long-term revenue growth in its core diabetes franchise.
While international expansion, especially in emerging markets and branded generics, is currently driving growth, overdependence on these geographies exposes Abbott to risks from changing regulatory policies, government price controls, and currency fluctuations, potentially making future earnings less predictable.
Ongoing litigation risk (e.g., infant formula MDL), regulatory hurdles (including potential for stricter or lengthier device and biosimilar approval processes), and the need for significant R&D and SG&A investment to support new product development and launches may raise costs, delay time-to-market, and impact overall profitability and net margins over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $116.54 for Abbott Laboratories based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $135.0, and the most bearish reporting a price target of just $92.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $59.6 billion, earnings will come to $9.5 billion, and it would be trading on a PE ratio of 26.9x, assuming you use a discount rate of 7.9%.
Given the current share price of $90.62, the analyst price target of $116.54 is 22.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Abbott Laboratories?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead